Equinor's stock has gained ground over the past month, yet a detailed fair value analysis suggests the Norwegian energy giant may be trading at a premium. Investors are weighing strong long-term momentum against future headwinds from the green shift.
Specialty insurer Kinsale Capital Group continues to outpace broader industry growth in key metrics, driven by its focus on underserved, higher-risk markets. However, its premium valuation and recent stock volatility have intensified debate among investors about its long-term sustainability.
Despite a sharp sell-off in its shares, HubSpot reports a surge in new contract signings and projects an expanding free cash flow margin, signaling underlying operational strength even as investors remain wary.
Conagra Brands launches its protein-packed Banquet MEGA Breakfast Bowls, a direct challenge to rivals in the frozen aisle. While the move aligns with consumer trends, analysts question if it's enough to offset broader financial pressures facing the packaged food giant.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
As Bob Iger prepares for his second departure, the Disney CEO outlines a forward-looking mandate for his successor during an earnings call, emphasizing evolution in a dynamic media landscape.
While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
Analyst firm Benchmark increased its price target for specialty food distributor The Chefs' Warehouse (CHEF) to $84, maintaining a Buy rating. The move follows strong operational performance, including domestic acquisitions and double-digit international growth in the Middle East.
Citigroup initiates coverage of Dutch Bros Inc. with a Buy rating and an $82 price target, citing the drive-through coffee chain's successful national scaling and multiple drivers for sustained same-store sales growth over the coming years.
As the 2026 tax filing deadline approaches, new and expanded federal tax credits and deductions offer significant opportunities for filers to reduce their liability or increase their refund. Experts warn that millions overlook these benefits annually.
Southwest Airlines' stock just logged its biggest daily gain since 1978, fueled by a decisive break from its past. As bag fees, assigned seating, and new revenue streams take hold, the carrier's bold transformation is winning over Wall Street and setting the stage for a projected profit surge.
FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Despite posting blockbuster profits, Microsoft shares plunged 10% after its latest earnings, erasing hundreds of billions in market value. We examine whether Wall Street's reaction to cloud growth and AI spending fears is an overreaction or a prudent pause.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.
Advance Auto Parts (NYSE:AAP) remains a favored pick among hedge funds, even as Wall Street analysts offer conflicting price targets and ratings ahead of anticipated 2026 demand growth.
A common retirement strategy—delaying Social Security to maximize benefits—can have an unintended consequence for millions: significantly larger garnishments for federal debts. As the Treasury withholds percentages, not fixed sums, a bigger monthly check means a bigger automatic deduction.
Walmart is launching a cross-border shipping initiative early this year, enabling U.S.-based third-party sellers to directly reach consumers in Mexico and Canada, intensifying its e-commerce competition with Amazon.
